Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Genetics

Background:

• Diabetes mellitus (DM) patients face persistent cardiovascular risk despite controlled cholesterol.
• Elevated lipoprotein(a) [Lp(a)], an inherited particle, is a key contributor to this residual risk.
• Lp(a) promotes clot formation and vascular inflammation, independent of LDL cholesterol.

Purpose of the Study:

• To review the role of lipoprotein(a) [Lp(a)] in cardiovascular disease (CVD) risk for individuals with diabetes mellitus (DM).
• To highlight the limitations of conventional therapies and the potential of novel Lp(a)-targeted treatments.
• To emphasize the importance of Lp(a) measurement for risk assessment and treatment planning in diabetic populations.

Main Methods:

• Literature review synthesizing findings from laboratory and clinical studies.
• Analysis of Lp(a) pathophysiology, its association with diabetic complications, and treatment responses.
• Evaluation of RNA-based targeted agents (antisense oligonucleotides, siRNA) for Lp(a) reduction.

Main Results:

• Elevated Lp(a) levels (>30 mg/dL or >50 mg/dL) are independently linked to coronary artery disease, stroke, and microvascular complications in DM.
• Conventional lipid-lowering drugs have minimal impact on Lp(a) levels.
• RNA-based therapies demonstrate significant Lp(a) reduction (70-95%) in Phase 2 trials.

Conclusions:

• Lp(a) is a critical, often overlooked, risk factor in diabetes mellitus.
• Measuring Lp(a) at least once is recommended for all individuals, especially those with DM, for comprehensive risk assessment.
• Targeted Lp(a) therapies hold promise for redefining residual risk management and improving cardiovascular and microvascular outcomes in diabetic patients.